Parkinson's Disease (PD)
Pipeline by Development Stage
Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.
Key Trends
- Extreme market concentration: 68% of spending driven by one FXa inhibitor product
- Psychiatric and migraine therapies emerging as secondary growth drivers
- High clinical trial activity (8,279 trials) signals continued pipeline development
Career Verdict
Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 68% | Launch | Stable | 15.0yr |
| 2 | INVEGA SUSTENNA (paliperidone palmitate) | Johnson & Johnson | $1.8B | 7% | Peak | Stable | 4.7yr |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | Peak | Stable | 10.2yr |
| 4 | NUPLAZID (pimavanserin tartrate) | Acadia Pharmaceuticals | $596M | 2% | Peak | Stable | 10.9yr |
| 5 | INVEGA TRINZA (paliperidone palmitate) | Johnson & Johnson | $530M | 2% | Peak | Stable | 15.6yr |
Drug Class Breakdown
market-defining single product
stable mature class
niche but stable
specialty indication focus
emerging growth segment
stable with LOE risk
diverse small products
Career Outlook
StableNeurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.
Breaking In
Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.
For Experienced Professionals
Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.
In-Demand Skills
Best For
Hiring Landscape
Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.
Top Hiring Companies
By Department
Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.
Competitive Landscape
13 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 28 trials with date data
Clinical Trials (28)
Total enrollment: 3,002 patients across 28 trials
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)
A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
A Study of Buntanetap in Participants With PD
A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease
Phase I Clinical Study of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning Surgery
Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites
Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics
Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa
Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
Automated Image-Guided Programming of Deep Brain Stimulation (DBS) for Parkinson's Disease
Cerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Parkinson's Disease Tremor
Shanghai Clinical Cohort - Parkinson's Disease (Reserve)
Coordinated Reset Deep Brain Stimulation
COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel
Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy
Related Jobs in Neurology
Mechanical Engineer Intern
Neuroscience Account Manager - Cedar Rapids, IA
Infirmier.e / Technicien.ne en électrophysiologie (F/H)
Full Stack Software Engineer
Manager, People Operations
Sr. Litigation Paralegal
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.